X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CV07050101
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
Expanded trial analysis is expected to allow for collection of relevant efficacy data which includes the important group of approximately 270 participants above the age of 60, treated with 12µg of CVnCoV.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CV07050101
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
Over the course of the rolling submission process, EMA will assess CVnCoV’s compliance with standards for vaccine efficacy, safety, and pharmaceutical quality on the basis of individually submitted data packages as a prerequisite for a formal market authorization application.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rezafungin
Therapeutic Area: Infections and Infectious Diseases Product Name: CD101
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Cidara Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
Rezafungin is a novel, once-weekly echinocandin, currently in Phase 3 clinical trials for both the treatment of invasive candidiasis and prophylaxis against severe invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CV07050101
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: CureVac
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 07, 2021
Details:
Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: University Medical Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a two-dose schedule of 12 µg. The trial follows an epidemiological, non-interventional study conducted with healthcare workers from the University Hospital in Mainz.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
